{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:34:28Z","timestamp":1793457268733,"version":"4.5.0"},"reference-count":133,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Dermatology Foundation Diversity Research Supplement Award"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2022,11,17]]},"DOI":"10.1080\/09546634.2022.2114783","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T16:37:43Z","timestamp":1660840663000},"page":"3086-3097","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review"],"prefix":"10.1080","volume":"33","author":[{"given":"Anjana","family":"Sevagamoorthy","sequence":"first","affiliation":[{"name":"Deparment of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2569-9447","authenticated-orcid":false,"given":"Patrick","family":"Sockler","sequence":"additional","affiliation":[{"name":"Deparment of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Akoh","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9650-9738","authenticated-orcid":false,"given":"Junko","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Deparment of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Ewert S. US population trends: 2000 to 2060. 2015. Available from: https:\/\/www.ncsl.org\/Portals\/1\/Documents\/nalfo\/USDemographics.pdf"},{"key":"e_1_3_3_3_1","unstructured":"Congress.Gov. NIH revitalization act. Subtitle B: \u00a7131-133. 1993. Available from: https:\/\/www.congress.gov\/bill\/103rd-congress\/senate-bill\/1"},{"key":"e_1_3_3_4_1","unstructured":"NIH.Gov. NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research. 2017. Available from: https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-OD-18-014.html"},{"key":"e_1_3_3_5_1","unstructured":"FDA.gov. FDASIA section 907: inclusion of demographic subgroups in clinical trials. 2018. Available from: https:\/\/www.fda.gov\/regulatory-information\/food-and-drug-administration-safety-and-innovation-act-fdasia\/fdasia-section-907-inclusion-demographic-subgroups-clinical-trials"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28575"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000002027"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.4129"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5596"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20740"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2021.02.007"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.052"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2012.01797.x"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18938"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19468"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/08989620490891412"},{"issue":"11","key":"e_1_3_3_17_1","first-page":"25","article-title":"BPX-01 minocycline topical gel shows promise for the treatment of moderate-tosevere inflammatory acne vulgaris","volume":"11","author":"Alexis A","year":"2018","unstructured":"Alexis A, Del Rosso JQ, Desai SR, et\u00a0al. BPX-01 minocycline topical gel shows promise for the treatment of moderate-tosevere inflammatory acne vulgaris. J Clin Aesthetic Dermatol. 2018;11(11):25\u201335.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.033"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0265-y"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1046"},{"issue":"6","key":"e_1_3_3_21_1","first-page":"677","article-title":"Topical treatment with an agent disruptive to P. acnes biofilm provides positive therapeutic response: results of a randomized clinical trial","volume":"15","author":"Bernhardt MJ","year":"2016","unstructured":"Bernhardt MJ, Myntti MF. Topical treatment with an agent disruptive to P. acnes biofilm provides positive therapeutic response: results of a randomized clinical trial. J Drugs Dermatol. 2016;15(6):677\u2013683.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"e_1_3_3_22_1","first-page":"15","article-title":"Safety and efficacy of a halobetasol 0.01%\/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: a comparison with halobetasol propionate 0.05% cream","volume":"11","author":"Bhatia ND","year":"2018","unstructured":"Bhatia ND, Pariser DM, Kircik L, et\u00a0al. Safety and efficacy of a halobetasol 0.01%\/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: a comparison with halobetasol propionate 0.05% cream. J Clin Aesthet Dermatol. 2018;11(11):15\u201319.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13551"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17932"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14647"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1115819"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15722"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16890"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13348"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.048"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13768"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15150"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.03.013"},{"issue":"12","key":"e_1_3_3_36_1","first-page":"1496","article-title":"Results of a phase 2, randomized,Vehicle-Controlled study evaluating the efficacy, tolerability, and safety of daily or twice daily SB204 for the treatment of acne vulgaris","volume":"15","author":"Eichenfield LF","year":"2016","unstructured":"Eichenfield LF, Gold LS, Nahm WK, et\u00a0al. Results of a phase 2, randomized,Vehicle-Controlled study evaluating the efficacy, tolerability, and safety of daily or twice daily SB204 for the treatment of acne vulgaris. J Drugs Dermatol. 2016;15(12):1496\u201315027.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"e_1_3_3_37_1","first-page":"962","article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Eichenfield LF","year":"2016","unstructured":"Eichenfield LF, Lain T, Frankel EH, et\u00a0al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(8):962\u2013969.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.029"},{"issue":"2","key":"e_1_3_3_39_1","first-page":"154","article-title":"DFD-01, a novel medium potency betamethasone dipropionate 0.05% emollient spray, demonstrates similar efficacy to augmented betamethasone dipropionate 0.05% lotion for the treatment of moderate plaque psoriasis","volume":"15","author":"Fowler JF","year":"2016","unstructured":"Fowler JF, Hebert AA, Sugarman J. DFD-01, a novel medium potency betamethasone dipropionate 0.05% emollient spray, demonstrates similar efficacy to augmented betamethasone dipropionate 0.05% lotion for the treatment of moderate plaque psoriasis. J Drugs Dermatol. 2016;15(2):154\u2013162.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"e_1_3_3_40_1","first-page":"873","article-title":"Efficacy and safety of toreforant, a selective histamine h4 receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis: results from a phase 2 multicenter, randomized, double-blind, placebo-controlled trial","volume":"17","author":"Frankel E","year":"2018","unstructured":"Frankel E, Song M, Li S, et\u00a0al. Efficacy and safety of toreforant, a selective histamine h4 receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis: results from a phase 2 multicenter, randomized, double-blind, placebo-controlled trial. J Drugs Dermatol. 2018;17(8):873\u2013879.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.679"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.020"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.040"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.048"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.058"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012"},{"issue":"10","key":"e_1_3_3_50_1","first-page":"1062","article-title":"Safety and efficacy of a once-daily halobetasol propionate 0.01% lotion in the treatment of moderate-to-severe plaque psoriasis: results of two phase 3 randomized controlled trials","volume":"17","author":"Green LJ","year":"2018","unstructured":"Green LJ, Kerdel FA, Cook-Bolden FE, et\u00a0al. Safety and efficacy of a once-daily halobetasol propionate 0.01% lotion in the treatment of moderate-to-severe plaque psoriasis: results of two phase 3 randomized controlled trials. J Drugs Dermatol. 2018;17(10):1062\u20131069.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.018"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.016"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.001"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.02.034"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13112"},{"key":"e_1_3_3_57_1","first-page":"33","article-title":"Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis","volume":"11","author":"Khattri S","year":"2018","unstructured":"Khattri S, Goldblum O, Solotkin K, et\u00a0al. Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis. J Clin Aesthetic Dermatol. 2018;11:33\u201337.","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"8","key":"e_1_3_3_58_1","first-page":"912","article-title":"A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3\u2009mcg\/g ointment) when compared to betamethasone diproprionate ointment (64\u2009mg\/g) in patients with nail psoriasis","volume":"13","author":"Kole L","year":"2014","unstructured":"Kole L, Cantrell W, Elewski B. A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3\u2009mcg\/g ointment) when compared to betamethasone diproprionate ointment (64\u2009mg\/g) in patients with nail psoriasis. J Drugs Dermatol. 2014;13(8):912\u2013915.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16426"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.15171\/jlms.2015.13"},{"key":"e_1_3_3_66_1","first-page":"1468","article-title":"Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris\u2013a randomized phase III study (PSO-FAST","volume":"14","author":"Leonardi C","year":"2015","unstructured":"Leonardi C, Bagel J, Yamauchi P, et\u00a0al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris\u2013a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14:1468\u20131477.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"e_1_3_3_67_1","first-page":"922","article-title":"A randomized, prospective, sham-controlled study of localized narrow-band UVB phototherapy in the treatment of plaque psoriasis","volume":"13","author":"Levin AA","year":"2014","unstructured":"Levin AA, Aleissa S, Dumont N, et\u00a0al. A randomized, prospective, sham-controlled study of localized narrow-band UVB phototherapy in the treatment of plaque psoriasis. J Drugs Dermatol. 2014;13(8):922\u2013926.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.007394"},{"issue":"6","key":"e_1_3_3_69_1","first-page":"581","article-title":"Efficacy and safety of subantimicrobial dose, Modified-Release doxycycline 40\u2009mg versus doxycycline 100\u2009mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, Double-Blinded, controlled study","volume":"14","author":"Moore A","year":"2015","unstructured":"Moore A, Ling M, Bucko A, et\u00a0al. Efficacy and safety of subantimicrobial dose, Modified-Release doxycycline 40\u2009mg versus doxycycline 100\u2009mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, Double-Blinded, controlled study. J Drugs Dermatol. 2015;14(6):581\u2013586.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"e_1_3_3_70_1","first-page":"987","article-title":"Once-daily oral sarecycline 1.5\u2009mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials","volume":"17","author":"Moore A","year":"2018","unstructured":"Moore A, Green LJ, Bruce S, et\u00a0al. Once-daily oral sarecycline 1.5\u2009mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987\u2013996.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.011"},{"key":"e_1_3_3_72_1","first-page":"16","article-title":"The phototoxic and photoallergy potential of clindamycin phosphate 1.2%\/tretinoin 0.025% gel for facial acne: results of two single-center, evaluator-blinded, randomized, vehicle-controlled phase 1 studies in healthy volunteers","volume":"13","author":"Murray J","year":"2014","unstructured":"Murray J, Potts A. The phototoxic and photoallergy potential of clindamycin phosphate 1.2%\/tretinoin 0.025% gel for facial acne: results of two single-center, evaluator-blinded, randomized, vehicle-controlled phase 1 studies in healthy volunteers. J Drugs Dermatol. 2014;13:16\u201322.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_73_1","first-page":"25","article-title":"Efficacy and tolerability of a combined 445nm and 630nm over-the-counter light therapy mask with and without topical salicylic acid versus topical benzoyl peroxide for the treatment of mild-to-moderate acne vulgaris","volume":"9","author":"Nestor MS","year":"2016","unstructured":"Nestor MS, Swenson N, Macri A, et\u00a0al. Efficacy and tolerability of a combined 445nm and 630nm over-the-counter light therapy mask with and without topical salicylic acid versus topical benzoyl peroxide for the treatment of mild-to-moderate acne vulgaris. J Clin Aesthet Dermatol. 2016;9:25\u201335.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.046"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13745"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-016-0051-4"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_3_3_85_1","first-page":"234","article-title":"Two multicenter, randomized, Double-Blind, parallel group comparison studies of a novel enhanced lotion formulation of halobetasol propionate, 0.05% versus its vehicle in adult subjects with plaque psoriasis","volume":"16","author":"Pariser D","year":"2017","unstructured":"Pariser D, Gold LS, Kircik LH, et\u00a0al. Two multicenter, randomized, Double-Blind, parallel group comparison studies of a novel enhanced lotion formulation of halobetasol propionate, 0.05% versus its vehicle in adult subjects with plaque psoriasis. J Drugs Dermatol. 2017;16:234\u2013240.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14345"},{"issue":"9","key":"e_1_3_3_87_1","first-page":"1083","article-title":"An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris","volume":"13","author":"Pariser DM","year":"2014","unstructured":"Pariser DM, Rich P, Cook-Bolden FE, et\u00a0al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2014;13(9):1083\u20131089.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13859"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.047"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17628"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17351"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.037"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2047"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606490"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16736"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16004"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.043"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.059"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.017"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0178-4"},{"issue":"5","key":"e_1_3_3_107_1","first-page":"553","article-title":"Efficacy and safety of Once-Daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Stein Gold LF","year":"2016","unstructured":"Stein Gold LF, Jarratt MT, Bucko AD, et\u00a0al. Efficacy and safety of Once-Daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(5):553\u2013561.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"e_1_3_3_108_1","first-page":"801","article-title":"Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study","volume":"16","author":"Strober B","year":"2017","unstructured":"Strober B, Bagel J, Lebwohl M, et\u00a0al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16(8):801\u2013808.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_109_1","first-page":"197","article-title":"A phase 2, multicenter, Double-Blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol\/tazarotene fixed combination in the treatment of plaque psoriasis","volume":"16","author":"Sugarman JL","year":"2017","unstructured":"Sugarman JL, Gold LS, Lebwohl MG, et\u00a0al. A phase 2, multicenter, Double-Blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol\/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16:197\u2013204.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.044"},{"key":"e_1_3_3_111_1","first-page":"542","article-title":"2, Multicenter, Double-Blind, randomized, Vehicle-Controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-Severe acne vulgaris","volume":"18","author":"Tanghetti EA","year":"2019","unstructured":"Tanghetti EA, Kircik LH, Green LJ, et\u00a0al. A Phase 2, Multicenter, Double-Blind, randomized, Vehicle-Controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-Severe acne vulgaris. J Drugs Dermatol. 2019;18:542.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13814"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00388-8"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"issue":"10","key":"e_1_3_3_115_1","first-page":"1084","article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older","volume":"17","author":"Tyring SK","year":"2018","unstructured":"Tyring SK, Kircik LH, Pariser DM, et\u00a0al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084\u20131091.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_3_3_116_1","first-page":"665","article-title":"Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne","volume":"13","author":"Webster GF","year":"2014","unstructured":"Webster GF, Leyden JJ, Gross JA. Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne. J Drugs Dermatol. 2014;13(6):665\u2013670.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-014-0052-3"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2110-5"},{"key":"e_1_3_3_120_1","unstructured":"Data.census.gov DP05 ACS DEMOGRAPHIC AND HOUSING ESTIMATES in US census bureau 2015\u20132019 American community survey 5-year estimates. 2019. Available from: https:\/\/data.census.gov\/cedsci\/table?t=American%20Indian%20and%20Alaska%20Native%3AAsian%3ABlack%20or%20African%20American%3AHispanic%20or%20Latino%3ARace%20and%20Ethnicity%3ASome%20Other%20Race%3ATwo%20or%20More%20Races%3AWhite&tid=ACSDP5Y2019.DP05&tp=false"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2007"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.052"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.022"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11213"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.21.2458"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23157"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301706"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481602300404"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1080\/13557858.1997.9961813"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(00)00178-7"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256994"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08672.x"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2019.08.006"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13304"}],"container-title":["Journal of Dermatological Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09546634.2022.2114783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T22:55:59Z","timestamp":1715900159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2022.2114783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":133,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,11,17]]}},"alternative-id":["10.1080\/09546634.2022.2114783"],"URL":"https:\/\/doi.org\/10.1080\/09546634.2022.2114783","relation":{},"ISSN":["0954-6634","1471-1753"],"issn-type":[{"value":"0954-6634","type":"print"},{"value":"1471-1753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}